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Abstract
Introduction: Candidemia in critically ill patients is usually a severe and life-threatening condition with a high
crude mortality. Very few studies have focused on the impact of candidemia on ICU patient outcome and
attributable mortality still remains controversial. This study was carried out to determine the attributable mortality
of ICU-acquired candidemia in critically ill patients using propensity score matching analysis.
Methods: A prospective observational study was conducted of all consecutive non-neutropenic adult patients
admitted for at least seven days to 36 ICUs in Spain, France, and Argentina between April 2006 and June 2007. The
probability of developing candidemia was estimated using a multivariate logistic regression model. Each patient
with ICU-acquired candidemia was matched with two control patients with the nearest available Mahalanobis
metric matching within the calipers defined by the propensity score. Standardized differences tests (SDT) for each
variable before and after matching were calculated. Attributable mortality was determined by a modified Poisson
regression model adjusted by those variables that still presented certain misalignments defined as a SDT > 10%.
Results: Thirty-eight candidemias were diagnosed in 1,107 patients (34.3 episodes/1,000 ICU patients). Patients with
and without candidemia had an ICU crude mortality of 52.6% versus 20.6% (P < 0.001) and a crude hospital
mortality of 55.3% versus 29.6% (P = 0.01), respectively. In the propensity matched analysis, the corresponding
figures were 51.4% versus 37.1% (P = 0.222) and 54.3% versus 50% (P = 0.680). After controlling residual confusion
by the Poisson regression model, the relative risk (RR) of ICU- and hospital-attributable mortality from candidemia
was RR 1.298 (95% confidence interval (CI) 0.88 to 1.98) and RR 1.096 (95% CI 0.68 to 1.69), respectively.
Conclusions: ICU-acquired candidemia in critically ill patients is not associated with an increase in either ICU or
hospital mortality.
Introduction
Candida spp. are the fourth most common cause of
bloodstream infection in hospitalized patients [1-4] and a
leading cause of invasive fungal infection in the ICU set-
ting [1]. Candidemia in critically ill patients is usually a
severe and life-threatening condition with a high crude
mortality ranging between 35% and 75% [5,6]. In contrast,
candidemia-attributable mortality is unclear, with studies
showing high rates of 14.5% to 49% and others failing to
demonstrate any significant increase in mortality [7].
Infection caused by Candida spp. develops in patients
with multiple risk factors and severe underlying diseases,
so that it is difficult to distinguish mortality attributed to
candidemia from mortality related to the underlying ill-
ness. Thus, there is an interest in conducting case-control
or matched cohort studies in which attributable mortality
is obtained after matching and adjusting for confounding
variables. Despite these techniques it seems almost impos-
sible to match all factors (observable and unobservable)
than can potentially have an influence upon mortality.
This obstacle was overcome by Rosenbaum and Rubin [8]
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in 1983 who suggested matching ‘cases’ and ‘controls’
solely on their ‘propensity score’ - the estimated probabil-
ity of being a ‘case’ given observable characteristics. In a
scenario of ICU-acquired candidemia, each patient with
candidemia is matched to a patient without candidemia
who is most similar in terms of being a candidemic
patient, where this probability is calculated on the basis of
individual characteristics. Once the two groups are
formed, the average effect is estimated for each outcome
by simply computing the difference in means between the
two groups. In recent years, the use of propensity score
analysis in observational studies has increased considerably
[9].
This study was designed to determine the attributable
mortality of ICU-acquired candidemia in non-neutropenic
critically ill patients using propensity score matching
analysis.
Materials and methods
Design and study population
This was a prospective, cohort, observational and multi-
center study to assess candidemia-attributable mortality
in non-neutropenic adult ICU patients. Patients over the
age of 18 years who were admitted for at least seven days
to 36 medical-surgical ICUs of 32 tertiary care hospitals
in Spain, three in Argentina, and one in France between
April 2006 and June 2007 were eligible. Exclusion criteria
were age under 18 years, neutropenia defined as a total
leukocyte count ≤500/mm3 for more than three weeks,
life expectancy of less than a week, pregnant women and
nursing mothers, fungal infections other than those
caused by Candida spp., patients who had Candida spp.
isolation or were treated with antifungal drugs during the
first seven days of ICU admission, and refusal to give
informed consent. The study protocol was approved by
the Ethics Committee of the participating centers and
informed consent was obtained from patients or patient’s
representatives to participate in the study and publication
of results.
Data collection
For all patients during their ICU stay, screening for
Candida colonization was performed once a week using
routine samples from a digestive focus (feces and gastric
or pharyngeal aspirates), urine, skin, respiratory samples
and peripheral blood. Other samples from vascular cathe-
ters, wound or drainage exudates, or other infected foci
could be obtained at the discretion of the attending
physician. Results were considered positive in the
presence of Candida growth in the culture medium.
Candidemia was defined as at least one blood culture
positive for Candida spp. The onset of candidemia was
defined as the day when the first positive blood culture
was obtained. The different Candida isolates were identi-
fied at the species level. All catheter tips removed were
cultured in blood agar and Sabouraud Dextrose agar
(Difco Laboratories, Detroit, Mich.) by the Maki roll plate
technique [10]. Catheter-related candidemia required the
isolation of the same Candida species from blood and
catheter segment when the semiquantitative catheter tip
culture yielded more than 15 colony-forming units (CFU)
[11]. Candida peritonitis is defined as the isolation of
Candida spp. in a peritoneal sample obtained by laparot-
omy or percutaneous puncture in patients with associated
clinical findings. Time to antifungal therapy was defined
as the time interval between when the first positive Can-
dida blood culture was obtained and the time when anti-
fungal therapy was initiated. We measured time to
antifungal initiation in 24-hour increments and categor-
ized these times as day 0 (0 to 24 hours), day one (24 to
48 hours), day three (48-72 hours) and so on. Due to the
observational aspect of this study, the choice of antifungal
agent was left to the discretion of the treating physicians.
The use of fluconazole was assumed to be inappropriate
if it was prescribed for fungal bloodstream infections
caused by C. Krusei or C. glabrata (if it was resistant or
no susceptibility testing was done). Patients were followed
until discharge from the ICU, discharge from the hospi-
tal, or death. The following variables were recorded: age,
sex, date of ICU admission, dates of ICU and hospital
discharge, reason for ICU admission, underlying diseases,
concomitant infections, previous treatment with antibio-
tics or corticosteroids, and risk factors. According to
diagnoses at the time of ICU admission, patients were
classified as surgical, trauma, or medical. Type of surgery
(abdominal, non abdominal, elective, urgent) and number
of major procedures performed before and during ICU
stay were recorded. Medical patients undergoing major
surgery during ICU stay were considered surgical
patients. Underlying diseases included insulin-dependent
diabetes mellitus, neurological conditions, chronic
obstructive pulmonary disease (COPD), chronic liver dis-
ease, chronic renal failure and severe heart failure. Risk
factors included the following: treatment with corticoster-
oids with a daily dose equivalent to 20 mg prednisone for
at least two weeks, use of broad spectrum antibiotics or
antimicrobial drugs within ten days prior to the study,
use of mechanical ventilation and urinary catheter in
place on the day of enrollment. Central venous catheters,
arterial catheters, total parenteral nutrition, enteral nutri-
tion and renal replacement therapy were also recorded.
The Acute Physiology and Chronic Health Evaluation
(APACHE II) score [12] and the Sequential Organ Failure
Assessment (SOFA) score [13] were recorded on ICU
admission, once a week thereafter, and at the time of start-
ing antifungal treatment. Sepsis, severe sepsis, and septic
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shock were defined according to international sepsis defi-
nitions [14].
Statistical analysis
Categorical variables are expressed as frequencies and per-
centages, and continuous variables as mean and standard
deviation (SD) when data followed a normal distribution,
or as median and interquartile (IQR) (25th to 75th percen-
tile) range when distribution departed from normality.
Categorical variables were compared with the chi-square
(c2) test or the Fisher’s exact probability test, the means by
the Student’s t test and the medians by the Kruskal-Wallis
test. Risk factors for death among candidemic ICU
patients were determined using the Cox proportional-
hazard regression model. The probability of developing
candidemia was estimated using a multivariate logistic
regression model that incorporated demographic data,
length of ICU stay, severity indexes, comorbidities, and
risk factors [15]. Variables with statistical significance in
univariate analysis (P < 0.2) and variables of clinical rele-
vance were included in the model. We judged that estima-
tion of missing data was not required since in 91.6% of the
patients (1,014) all data were complete (three patients with
candidemia had missing data). The discriminatory power
of the model was evaluated by the Hosmer-Lemeshow
goodness-of-fit test and calculating the area under the
receiver operating characteristics (ROC) curve (AUC). The
model was considered to have good discriminatory power
when AUC was greater than or equal to 0.80. Each patient
with ICU-acquired candidemia was matched to the two
control patients with the nearest available Mahalanobis
metric matching within calipers determined by the pro-
pensity score. The caliper was defined as one quarter of
the standard deviation of the logit of the propensity score
[16]. To determine the effectiveness of propensity score
matching in controlling for differences between patients
with and without candidemia, the standardized differences
tests (SDT) were calculated for each variable before and
after matching. The McNemar’s test was used to compare
crude mortality in the matched samples. Candidemia-attri-
butable mortality was determined by a modified Poisson
regression model with a robust error variance adjusted by
those variables that still presented certain misalignment
defined as a SDT > 10% [17-19]. Statistical analyses were
performed with SPSS 15.0 (SPSS Inc., Chicago, Illinois)
and SAS 9.1 software (SAS Institute, Inc, Cary, NC).
Results
A total of 1,107 patients fulfilled the inclusion criteria and
were included in the study. Thirty-eight patients (3.4%)
developed candidemia, with an incidence rate of 34.3 epi-
sodes of candidemia per 1,000 ICU patients and 1.48 epi-
sodes per 1,000 days of ICU stay (95% CI 1.05 to 2.03
episodes per 1,000 patient-days). Baseline characteristics of
the study population according to the presence or absence
of candidemia are shown in Table 1.
The median duration from ICU admission to the onset
of candidemia was 14 days (IQR 8.75 to 19.25 days).
Abdominal surgery was the diagnosis on ICU admission in
31 (81.6%) patients. Infections were caused by C. albicans
in 22 episodes, C. parapsilosis in nine, C. tropicalis in
three, C. glabrata in two, C. krusei in one and Candida
ssp. in one. The distribution of variables including severity
indexes, ICU length of stay and mortality was similar in
patients with candidemia caused by C. albicans and non-
albicans Candida spp. As for the source of candidemia,
infection of unknown origin was reported as the most fre-
quent (n = 29, 76.3%) followed catheter-related infections
(n = 8, 21.1%). One patient had candidemia and peritonitis
concomitantly (2.6%). Multifocal colonization was a clini-
cally relevant condition which was present in up to 91.4%
of all patients before the development of candidemia.
C. parapsilosis was the most frequently isolated species
among the non-albicans spp in bloodstream infections and
had a lower crude mortality (33%). Seven patients were
not given antifungals and all of them died. Thirty-one
patients were given antifungal treatment and in all cases
the selection of the antifungal drug was appropriate
according to the Candida spp. isolated. The following
antifungal agents were used either as the sole agent
throughout the course of treatment, or in a sequential pat-
tern resulting in the use of multiple agents for a single epi-
sode (that is, de-escalation): fluconazole was used most
often (n = 21, 67.7%), followed by amphotericin B-based
(BL/CL) preparations (n = 7, 22.6%), caspofungin (n = 6,
19.4%) and voriconazole (n = 4, 12.9%). The median time
for initiation of antifungal therapy was one day (IQR 0 to
4 days). In two patients with candidemia (5.7%), antifungal
treatment was administered preemptively on the same day
as material for blood culture was collected (day 0). The
rest of the patients with candidemia were treated with tar-
geted antifungal treatment after notification of a positive
Candida blood culture result. Nearly one third of the epi-
sodes (n = 12, 31.6%) were treated between 24 and 48
hours (day one) after blood cultures were obtained (in
some cases before final Candida species identification).
The crude ICU mortality rate was 52.6% (20/38) in
patients with candidemia and 20.6% (220/1,069) in those
without candidemia (P < 0.001). The crude hospital death
rate was 55.3% (21/38) and 29.6% (314/1,069) among
patients with and without candidemia, respectively (P =
0.01).
In the univariate analysis, age (hazard ratio (HR) 1.03,
95% CI 1.0 to 1.06; P = 0.032), APACHE II score on ICU
admission (HR 1.09, 95% CI 1.12 to 1.81; P = 0.013),
APACHE II score at diagnosis of candidemia (HR 1.13,
95% CI 1.03 to 1.24; P = 0.006), SOFA score at diagnosis
of candidemia (HR 1.14, 95% CI 1.03 to 1.27; P = 0.011),
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Age, years, mean (SD) 60.0 ± 17.1 59.0 ± 17.9 .706 5.7%
Male/female (%) 67.4/32.6 63.2/36.8 .583 8.8%
APACHE II score at ICU admission, mean (SD) 18.3 ± 7.0 20.1 ± 6.5 .131 -19.24%
SOFA score at ICU admission 7 (4 to 9) 8.5 (7 to 10) .004
ICU length of stay (days)a 17 (12 to 28) 28.5 (16.5 to 53.5) .001
Hospital length of stay (days)a 37 (23 to 59) 37 (26 to 67) .436
ICU mortality, number (%) 220 (20.6) 20 (52.6)) < .001
Overall mortality, number (%) 314 (29.6) 21 (55.3) .001
Diagnosis on ICU admission, number (%) .437
Medical 523 (48.9) 16 (42.1) -13.68%
Surgical 369 (34.5) 17 (44.7) 20.97%
Trauma 177 (16.6) 5 (13.2) -9.55
Multifocal colonization, total, number (%) 649 (60.7) 35 (92.1) < .001 79.58%
Clinical condition, number (%) at the time of ICU admission < .001
No sepsis 497 (46.6) 1 (2.6) -118.8%
Sepsis 297 (27.9) 11 (28.9) 2.22%
Severe sepsis 108 (10.1) 11 (28.9) 48.84%
Septic shock 164 (15.4) 15 (39.5) 56.1%
Surgery, number (%) 369 (34.4) 17 (44.7) .202 21.18%
Abdominal surgery, number (%) 205 (19.2) 12 (31.6) .075 28.78%
Surgical procedures, number .302
None 625 (58.5) 20 (52.6) -11.89%
One 316 (29.6) 10 (26.3) -7.36%
Two or more 128 (12.0) 8 (21.1) 24.67
Secondary peritonitis, number (%) 65 (6.1) 4 (10.5) .306 16%
Underlying illnesses, number (%)
Neurologic disease 224 (21.0) 5 (13.2) .220 -20.83%
Trauma 197 (18.4) 7 (18.4) .999 0%
Diabetes mellitus 183 (17.1) 7 (18.4) .836 3.4%
COPD 163 (15.2) 9 (23.7) .183 21.6%
Heart failure 91 (8.5) 6 (15.8) .155 22.48%
Chronic renal failure 58 (5.4) 2 (5.3) .965 -0.44%
Acute coronary syndrome 51 (4.8) 1 (2.6) .507 -11.67%
Chronic liver failure 45 (4.2) 1 (2.6) .609 -8.84%
Hematologic malignancy 12 (1.1) 0 .359 -14.91%
Solid tumor 124 (11.6) 4 (10.5) .837 -3.51%
Risk factors, number (%)
Urinary catheter 1,057 (99.1) 37 (97.4) .387 -12.99%
Central venous catheter 1,044 (97.8) 38 (100.0) .193 21.21%
Mechanical ventilation 967 (90.5) 37 (97.4) .097 29.24%
Broad-spectrum antibiotics 941 (88.3) 36 (97.3) .046 35.36%
Empiric/preemptive antifungal treatment. 180 (16.8) 2 (5.3) .032 -37.31%
Arterial catheter 846 (79.5) 37 (97.4) .001 58.33%
Enteral nutrition 825 (77.2) 26 (68.4) .225 -19.87%
Total parenteral nutrition 428 (40.4) 27 (71.1) < .001 64.99%
Corticosteroids 300 (28.5) 12 (31.6) .679 6.76%
Renal replacement therapy 126 (12.0) 15 (39.5) < .001 66.25%
aMedian (25th to 75th percentiles). APACHE, Acute Physiology and Chronic Health Score; COPD, Chronic Obstructive Pulmonary Disease; SD, standard deviation;
SDT, standardized difference; SOFA, Sequential Organ Failure Assessment.
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and delay in starting antifungal therapy for more than
72 hours (HR 2.95, 95% CI 1.21 to 7.20; P = 0.017) were
significantly associated with death. In the multivariate
analysis, APACHE II score at the time of diagnosis of
candidemia was the only predictor of death (adjusted HR
1.13, 95% CI 1.03 to 1.24; P = 0.006).
The logistic regression model used in propensity score
analysis showed a high discriminatory power with an AUC
value of 0.902. The standardized differences in the demo-
graphic and clinical variables of interest nearly disappeared
when matched patients were analyzed (Table 2). In the
matched study sample, the crude ICU mortality was 51.4%
in the group with candidemia and 37.1% in the group
without candidemia (P = 0.222). The crude hospital mor-
tality rate was 54.3% among candidemic patients and 50%
among non-candidemic patients (P = 0.680). After con-
trolling residual confusion using a Poisson regression
model, the risk of ICU candidemia-attributable mortality
was relative risk (RR) 1.298 (95% CI 0.88 to 1.98) and the
risk of hospital candidemia-attributable mortality was RR
1.096 (95% CI 0.68 to 1.69).
Discussion
General findings obtained in this study, including an inci-
dence rate of 34.3 episodes of candidemia per 1,000 ICU
patients and a crude mortality rate of 52.6% are consistent
with previously published data [5,20]. Attributable ICU
mortality to Candida-related bloodstream infection varies
largely and has been estimated to be non-significantly dif-
ferent from that of patients without candidemia or to be
higher by 5% to 40% [7,21,22]. For this reason, analysis in
matched cohort samples is recommended, although only
seven studies assessing attributable mortality of candide-
mia have been previously published [23]. Important limita-
tions are related to methodological heterogeneity,
including study design (usually retrospective), study popu-
lation (patients hospitalized in ICUs and hospital wards
and those undergoing transplantation), source of data
(hospital or microbiological databases) and matching cri-
teria mainly based on underlying disease and comorbidity,
rather than on all possible factors that may influence mor-
tality. Moreover, severity scores and length of ICU stay
were not considered.
In the present prospective and multicenter study, can-
didemia was not associated with an increase in either
ICU or hospital mortality. This finding may be explained
by the use of propensity matching score analysis to con-
trol for all potential confounding variables related to the
development of Candida spp. bloodstream infection.
Matching was highly effective and both candidemic and
non-candidemic groups had similar characteristics, dif-
fering only in the development of bloodstream infection.
These favorable results could be attributed to earlier
treatment of bloodstream infection and better monitoring
(weekly surveillance sampling). An early start of appropri-
ate antifungal therapy (within the critical time-frame of
the first 24 to 48 hours) is crucial for the reduction of
bloodstream infection-related mortality [24,25]. This
observation confirms the importance of an empirical and
preemptive strategy. Another important factor is the rapid
reporting of the microbiological results (positive blood-
stream infection and species identification) in order to
initiate targeted antifungal treatment or to modify pre-
vious empirical antifungal agents. In our study, the median
time for initiation of antifungal therapy was one day (IQR
0 to 4 days). In 36.9% of patients it was initiated within 48
hours of obtaining the first positive blood culture (5.2% of
them as preemptive treatment). Another important pro-
blem preventing the earlier recognition and treatment of
candidemia is the lack of specific clinical findings. Differ-
ent prediction rules based on a variety of risk factors,
including Candida species colonization are recommended
to identify patients at high risk for fungal bloodstream
infections [26,27]. High density colonization can be used
to identify patients who may benefit from preemptive anti-
fungal treatment in the appropriate clinical setting [28]. In
our study multifocal colonization was a clinically relevant
condition which was present in up to 92.1% of all patients
before the development of candidemia and there was a
high similarity between causative and colonized strains;
this could guide appropriate antifungal treatment. Addi-
tionally, an appropriate antifungal agent was administered
in all treated patients and this may also contribute to
increased survival. Moreover, earlier replacement of cen-
tral venous catheters, common practice in ICU’s, could
also reduce mortality. On the other hand, antifungal ther-
apy was initiated in 180 non-candidemic high-risk patients
(n = 180/1,069, 16.8%) as an empiric or preemptive strat-
egy. This antifungal strategy has not been evaluated in pre-
vious articles estimating candidemia-attributable mortality.
As this can be a major confounding factor, empirical or
preemptive treatment was introduced in the logistic
regression model. There was no difference in this variable
in the propensity score-matched patients as we list in
Table 2. It has been shown that ICU patients with candi-
demia have a substantially higher severity of illness on the
day of diagnosis compared with the ICU admission day
[29]. This is also an important disadvantage for matching
because severity scores are determined on ICU admission
but not at the time of developing candidemia. However,
after matching by the propensity score, APACHE II and
SOFA severity scores recorded weekly did not vary signifi-
cantly between cases and controls.
The crude ICU mortality in patients with candidemia
in our study is 52.6% with a median of five days from the
diagnosis until death. Due to the high mortality and poor
prognosis of patients with Candida spp. bloodstream
infection, there is a strong need to identify predictors of
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Age, years, mean (SD) 60.96 ± 17.3 59.2 ± 18.36 .641 9.86%
Male/female (%) 24 (34.3) 12 (34.3) 1 0%
APACHE II score at ICU admission, mean (SD) 19.07 ± 6.34 19.88 ± 6.29 .532 -12.82%
SOFA score at ICU admission 8 (4 to 10) 8 (7 to 10) .658
ICU length of stay (days)a 28.5 (17.75 to 40.25) 30 (17 to 58) .514
Hospital length of stay (dys)a 43 (28 to 69) 37 (27 to 70) .801
ICU mortality, number (%) 26 (37.1) 18 (51.4) .163
Overall mortality, number (%) 35 (50) 19 (54.3) .680
Diagnosis on ICU admission, number (%) .861
Medical 29 (41.4) 15 (42.9) 3%
Surgical 35 (50) 16 (45.7) 8.61%
Trauma 6 (8.6) 4 (11.4) -9.34%
Multifocal colonization, total, number (%) 67 (95.7) 32 (91.4) .398 -17.57
Clinical condition, number (%) at the time of ICU admission .459
No sepsis 6 (8.6) 1 (2.9) -24.67
Sepsis 17 (24.3) 11 (31.4) 15.89
Severe sepsis 12 (17.1) 9 (25.7) 21.08
Septic shock 35 (50) 14 (40) -20.2
Surgery, number (%) 35 (50) 16 (45.7) .680 -8.6
Abdominal surgery, number (%) 26 (37.1) 11 (31.4) .565 -12
Surgical procedures, number .961
None 34 (48.6) 18 (51.4) 5.6
One 19 (27.1) 9 (25.7) -3.7
Two or more 17 (24.3) 8 (22.9) -3.29
Secondary peritonitis, number (%) 9 (12.9) 3 (8.6) .517 -13.9
Underlying illnesses, number (%)
Neurologic disease 12 (17.1) 5 (14.3) .709 -7.7
Trauma 9 (12.9) 6 (17.1) .556 11.78
Diabetes mellitus 16 (22.9) 7 (20) .739 -7
COPD 18 (25.7) 8 (22.9) .749 -6.5
Heart failure 8 (11.4) 6 (17.1) .419 16.36
Chronic renal failure 4 (5.7) 2 (5.7) 1 0
Acute coronary syndrome 1 (1.4) 1 (2.9) 1 0
Chronic liver failure 3 (4.3) 0 .549 -29.97
Hematologic malignancy 1 (1.4) 0 1 -16.85
Solid tumor 7 (10) 4 (11.4) 1 -4.5
Risk factors, number (%)
Urinary catheter 70 (100) 34 (97.1) .333 -24.4
Central venous catheter 70 (100) 35 (100) - 0
Mechanical ventilation 69 (98.6) 35 (100) 1 16.8
Broad-spectrum antibiotics 69 (98.6) 34 (97.1) 1 -10.35
Empiric/preemptive antifungal treatment. 5 (7.1) 2 (5.7) 1 5.7
Arterial catheter 70 (100) 34 (97.1) .333 -24.4
Enteral nutrition 49 (70) 25 (71.4) .880 3
Total parenteral nutrition 55 (78.6) 25 (71.4) .418 -16.78
Corticosteroids 31 (44.3) 12 (34.3) .326 -20.58
Renal replacement therapy 24 (34.3) 14 (40) .566 11.8
aMedian (25th to 75th percentiles). APACHE, Acute Physiology and Chronic Health Score; COPD, Chronic Obstructive Pulmonary Disease; SD, standard deviation;
SDT, standardized difference; SOFA, Sequential Organ Failure Assessment.
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death. Factors associated with fatal outcome, such as age,
malnutrition, delay in removal of central venous catheter,
candidemia caused by non-albicans Candida spp. and
delay in starting antifungal therapy have been extensively
recognized [25,30-32]. However, in our study only APA-
CHEII score at the time of diagnosis of candidemia was a
predictor of mortality.
The lack of differences in mortality rates between the
groups of C. albicans and non-albicans Candida spp. may
be explained by different reasons: i) Adequacy of antifun-
gal therapy with all candidemias caused by Candida spp.
with a possible decreased sensitivity or resistance to azoles
being treated with candins or different formulations of
amphotericin B; ii) a relatively high percentage of cases
caused by C. parapsilosis (23.7%), associated with lower
mortality [1,33,34]; and iii) a systematic removal policy for
central venous catheters.
Two frequently cited studies [25,29] have shown an
association between mortality and delay in start antifungal
treatment. It should be noted that in both studies, the
majority of episodes of candidemia occurred in patients
admitted to hospital wards, with an in-hospital mortality
rate of about 30%. In our study, all patients had ICU-
acquired candidemia, with a higher crude mortality. It
may be possible that antifungal treatment is started earlier
in critically ill patients admitted to the ICU than in less
severely ill patients in the hospital wards where strict pro-
tocols of microbiological surveillance are not established.
Despite the fact that more than 1,000 patients were
recruited, the small number of candidemias related to
the incidence of invasive candidiasis in the critically ill
patient is a limitation of the study and might have com-
promised our power to detect differences in mortality
between cases and controls. Additionally, the sensitivity
of blood cultures for candidiasis is low (approximately
60%). This could impact the actual incidence of candide-
mia and also the overall mortality in the ICU. Therefore,
there is a possibility that patients with candidemia that
may have had identical matching risk factors but nega-
tive blood culture were considered matching controls
instead of cases.
Conclusions
In summary, ICU-acquired candidemia in critically ill
patients was not associated with an increase of either
ICU or hospital mortality. APACHE II at the time of
diagnosis of candidemia was the only predictor of death
in patients with candidemia.
Key messages
• Candidemia was not associated with an increase in
either ICU or hospital mortality.
• The use of propensity score matching analysis to
control for all potential confounding variables
allowed the assessment of candidemia-attributable
mortality in critically ill patients.
• Earlier treatment of bloodstream infection and bet-
ter monitoring (surveillance sampling weekly),
resulting in appropriate antifungal agent may contri-
bute to increased survival.
• APACHE II at the time of diagnosis of candidemia
was the only predictor of death in patients with
candidemia.
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